MoneyWorks4Me

Biocon’s arm featured on the prestigious Asia IP ELITE list for 2022 by lAM

11 Nov 2022 Evaluate

Biocon’s subsidiary -- Biocon Biologics has been featured on the prestigious Asia IP ELITE list for 2022 by lntellectual Asset Management (lAM) for its world class Intellectual Property (IP) management and IP value creation in the Asia-Pacific region.

Biocon was the first and only pharmaceutical company from India to be featured on the ASIA IP ELITE list in 2016. Biocon Biologics debuted on the list in 2019. This is the fifth consecutive year that a Biocon Group company has made it to the Asia lP ELITE list, which recognizes companies across the Asia-Pacific region that demonstrate a sustained commitment to building best-in-class in-house lP functions and continuous excellence in lP value creation.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Peers
Company Name CMP
Sun Pharma. Inds. 1782.00
Dr. Reddys Labs. 1208.00
Cipla 1334.00
Lupin 2010.00
Zydus Lifesciences 1138.50
View more..